inhalation therapy

37
Recommendations Recommendations for for Inhalation Inhalation Therapy Therapy (Focusing on (Focusing on bronchodilator) bronchodilator) 4A Intern 蔡蔡蔡

Upload: shilpa-prajapati

Post on 18-Nov-2014

3.354 views

Category:

Business


9 download

DESCRIPTION

 

TRANSCRIPT

Page 1: Inhalation therapy

Recommendations for Recommendations for Inhalation TherapyInhalation Therapy

(Focusing on bronchodilator)(Focusing on bronchodilator)

4A Intern

蔡宇承

Page 2: Inhalation therapy

Why and why not?

Advantages:

- Less systemic toxicity

- More rapid onset of medication

- Delivery to target of action

- Higher concentrations available in the lung Disadvantages:

- Time and effort consuming

- Limitation of delivery device

Page 3: Inhalation therapy

What are the Inhalant drugs? Antiallergic agents

Budesonide

Cromolyn sodium Bronchodilators

Ventolin nebules (βagonist)

Bricanyl solution (βagonist)

Atrovert nebulizer solution (anti- cholinergic)

Page 4: Inhalation therapy

Inhalant drugs

Mucolytic agents

Acetein (Acetylcysteine)

Mistabron (Mesna) Antimicrobials

Tobramycin

Pentamidine

Ribavirin

Amphotericin

Page 5: Inhalation therapy

Inhalant drugs

Immune modulators

Cyclosporine

Interferon α

Interferon γ Vaso-active

Prostacyclin

Nitric oxide

Page 6: Inhalation therapy

Inhalant drugs

Anesthetics

Opioids Other

Granulocyte-Macrophage Colony-Stimulating Factor

Surfactant

Interleukin II

Gene therapy vectors

Page 7: Inhalation therapy

Respiratory tract characteristics

Large surface area, good vascularization, immense capacity for solute exchange, ultra-thinness of the pulmonary epithelium

Conducting region :

Nasal cavity, nasopharynx, bronchi, bronchioles (first 16 generations)

Respiratory region :

respiratory bronchioles, alveolar ducts and sacs (17-23 generations)

Page 8: Inhalation therapy

Particle Size

MMAD: mass median aerodynamic diameter

MMAD <1μm: exhaledMMAD 1~5μm: targetMMAD >5μm: oropharynx

Strict control of MMAD of the particles ensures the reproducibility of aerosol deposition and retention.

Page 9: Inhalation therapy

Particle Size

Page 10: Inhalation therapy

Device for Inhalation Therapy

Selections of device include:– 1.Nebulizer(霧化器 ): small volume,

large volume, ultrasonic, pneumatic…– 2.Metered dose inhaler, MDI (定量吸入器 )– 3.Dry powder inhaler, DPI (粉末型吸入器 )

Page 11: Inhalation therapy

Metered-dose inhalers

A liquid propellant A metering valve that dispenses a constant volum

e of a solution or suspension of the drug in the propellant.

Inhalation technique is critical for optimal drug delivery – Actuating a MDI out of synchrony may cause negligible lower airway delivery

Mainly oropharyngeal deposition Protein denaturation

Page 12: Inhalation therapy

Metered-dose inhalers

Page 13: Inhalation therapy

Dry powder inhalers No propellant Breath-activated, and patient coordination is not

as important an issue. The drug is formulated in a filler and contained

in a capsule that is placed in the device and punctured to release the powder.

Proteins and macromolecules are more stable in dry powder form, this approach has been preferred for delivery of these compounds by the inhalational route

Page 14: Inhalation therapy

Nebulizers

Patient cooperation and coordination is not as critical

Commercially available nebulizers deliver 12% to 20% of the nebulized dose into the bronchial tree.

Heterogeneous drops Protein denaturation

Page 15: Inhalation therapy

Nebulizers

Page 16: Inhalation therapy

Nebulizers

Page 17: Inhalation therapy

Drugs Available for Nebulization

Inhaled beta-2 agonist bronchodilators– Short-acting (3~6hr)– Long-acting (>12hr)

Inhaled anti-cholinergics Inhaled corticosteroids

Page 18: Inhalation therapy

Inhaled Beta-2 Agonist Bronchodilators

Short-acting (3~6hr)– Salbutamol / Albuterol (Ventolin)– Terbutaline (Bricanyl)– Fenoterol (Berotec)

Long-acting (>12hr)– Salmeterol– Formoterol

Page 19: Inhalation therapy

Inhaled Anti-cholinergics

Ipratropium bromide (Atrovent)

Page 20: Inhalation therapy

Inhaled Corticosteroids

Beclomethasone Triamcinolone Flunisolide Budesonide (Pulmicort) Fluticasone

Page 21: Inhalation therapy

General Indications

Bronchodilator aerosol administration and evaluation of response is indicated whenever bronchoconstriction or increased airway resistance is documented or suspected in patients during mechanical ventilation

- AARC Clinical Practice Guideline

Page 22: Inhalation therapy

Criteria

Presence of one or more of the following criteria: Previous demonstrated response of bronchodilator Presence of auto-PEEP not eliminated by reduced rat

e, increased inspiratory flow, or decreased inspiratory to expiratory time ratio

Increased airway resistance evidenced by:• Increased peak inspiratory pressure and plateau pressure di

fference• Wheezing or decreased breathing sound• Intercostal or sternal retraction• Patient – ventilator dyssynchrony

Page 23: Inhalation therapy

Some Evidence Based Factsfrom American Journal of

Respiratory Critical Care Medicine

Page 24: Inhalation therapy

Mechanically Ventilated Patients (1)

Bronchodilator therapy is commonly used in the intensive care unit, although the indications for its use are not well defined

Patients with COPD demonstrate a significant decrease in airway resistance after administration of bronchodilators

Bronchodilators have been successfully used to treat acute bronchial spasm in the operating room, and they are widely used in mechanically ventilated patients with severe asthma

Inhaled Bronchodilator Therapy in Mechanically Ventilated Patients Am J Respir Crit Care Med Vol. 156. pp. 3-10, 1997

Page 25: Inhalation therapy

Mechanically Ventilated Patients (2)

A heterogeneous group of mechanically ventilated patients, including some patients without a previous diagnosis of airway obstruction, have shown improvement in their expiratory airflow after bronchodilator administration

Although ARDS is primarily a disease affecting the alveoli, nebulized metaproterenol sulfate produced a decrease in airway resistance in patients with this disorder

Inhaled Bronchodilator Therapy in Mechanically Ventilated PatientsAm J Respir Crit Care Med Vol. 156. pp. 3-10, 1997

Page 26: Inhalation therapy

Mechanically Ventilated Neonates and Infants (1)

Pressure-limited, time-cycled modes of mechanical ventilation are widely used in neonates and infants

Several investigators have reported that the small diameter of the endotracheal tubes and ventilator tubing and the low tidal volumes used for ventilating neonates and infants decrease aerosol delivery to the respiratory tract

Inhaled Bronchodilator Therapy in Mechanically Ventilated Patients Am J Respir Crit Care Med Vol. 156. pp. 3-10, 1997

Page 27: Inhalation therapy

Mechanically Ventilated Neonates and Infants (2)

The lung deposition to be as low as 0.98 ± 0.2% and 0.22 ± 0.1% with an MDI and spacer or a jet nebulizer, respectively

Even such low levels of drug deposition are adequate when considered in terms of the body weight of the patient (mg of drug deposited per kg body weight)

Inhaled Bronchodilator Therapy in Mechanically Ventilated Patients Am J Respir Crit Care Med Vol. 156. pp. 3-10, 1997

Page 28: Inhalation therapy

Mechanically Ventilated Neonates and Infants (3)

Inhaled beta-adrenergic and anticholinergic drugs are effective in ventilator-supported neonates and infants with acute, subacute, and chronic lung disease

The use of inhaled corticosteroids has also been advocated in infants with bronchopulmonary dysplasia

Inhaled Bronchodilator Therapy in Mechanically Ventilated Patients Am J Respir Crit Care Med Vol. 156. pp. 3-10, 1997

Page 29: Inhalation therapy

Current Guideline of Bronchodilator Usage in NTUH SICU

Ventoline: first choice as Bronchodilator to reduce airway resistance in mechanically ventilated patients

Atrovent: recommended to given patient with Asthma & COPD history, as a combination with Bronchodilator. Old age, long-term use, might be an indication of this combination also.

Pulmicort: first line to treat pulmonary inflammatory disease.

Give Ventoline before Pulmicort.

Page 30: Inhalation therapy

Indication for Bronchodilator (1)

Short-acting inhaled Beta-2 Agonist Bronchodilators– Acute asthma for quickly relieving symptoms– AECOPD, maybe can combine inhaled Anti-cholin

ergics– Stable COPD combine inhaled Anti-cholinergics f

or short term use seems more effective than either alone

– In mechanically ventilated patients which present auto-PEEP or evidently increased airway resistance

Page 31: Inhalation therapy

Indication for Bronchodilator (2)

Inhaled Anti-cholinergics– AECOPD can be used or be added to short-acting

inhaled beta-2 agonist bronchodilators– Stable COPD combine short-acting inhaled beta-2

agonist bronchodilators for short term use seems more effective than either alone

– In mechanically ventilated patients which present auto-PEEP or evidently increased airway resistance

Page 32: Inhalation therapy

AARC Recommendation I

Ventilator setting:

- tidal volume > 500

- Addition of inspiratory pulse (in case the inspiratory flow demands of the patient are met)

- Spontaneous breath should not be suppressed

Page 33: Inhalation therapy

AARC Recommendation II

Humidifier use:

- reduce aerosol delivery by 40%

- Humidified gas should still be used for dry gas associated risk

- Increase dose for compensation

Page 34: Inhalation therapy

AARC Recommendation III

Metered Dose Inhaler

- Delivered dose significantly reduced due to failure to actuate the inhaler with the onset of inspiration

- Actuate the inhaler manually for synchronizing the inspiration

Page 35: Inhalation therapy

AARC Recommendation IV

Nebulizer Use:

- Change nebulizer every 24 hours

- Leave it 30 cm proximal to endotracheal tube if possible

- It may be necessary to add a filter in the expiratory limb of the circuit to maintain expiratory flow-sensor accuracy

Page 36: Inhalation therapy

AARC Recommendation V

Patient monitoring:

- Volume ventilation: peak inspiratory pressure and the difference between peak and plateau pressure

- Pressure ventilation: tidal volume

- Auto-PEEP

- Peak Expiratory Flow and Flow-Volume Loop

- Breath Sound

Page 37: Inhalation therapy

Thank you for your attention!